TOP PAGE
ENGLISH
JAPANESE
|
CONNECT WITH US:
Home
About
Services
Contact
Log in
Home
Press release
Jan 11, 2023 12:52 JST
Source:
Eisai
Eisai Submits Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer's Disease in Europe
TOKYO, Jan 11, 2023 - (JCN Newswire) - Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) announced today that Eisai has submitted a marketing authorization application (MAA) for lecanemab (Brand Name in the U.S.: LEQEMBI), an investigational anti-amyloid beta (Abeta) protofibril antibody, for the treatment of early Alzheimer's disease (mild cognitive impairment due to Alzheimer's disease (AD) and mild AD dementia) to the European Medicines Agency (EMA). This application is based on the results of the Phase III Clarity AD study and the Phase IIb clinical study (Study 201), which demonstrated that lecanemab treatment showed a reduction of clinical decline in early AD, and is subject to a validation to determine whether the EMA accepts the application for review.
The Clarity AD study met its primary endpoint (CDR-SB(1): Clinical Dementia Rating-Sum of Boxes) and all key secondary endpoints with highly statistically significant results. The most common adverse events (>10%) in the lecanemab group were infusion reactions, ARIA-H (combined cerebral microhemorrhages, cerebral macrohemorrhages, and superficial siderosis), ARIA-E (edema/effusion), headache, and fall.
In November 2022, the results of the Clarity AD study were presented at the 2022 Clinical Trials on Alzheimer's Disease (CTAD) conference, and simultaneously published in the New England Journal of Medicine, peer-reviewed medical journals.
In the U.S., lecanemab was granted accelerated approval as a treatment for AD by the U.S. Food and Drug Administration (FDA) on January 6, 2023. Eisai submitted a Supplemental Biologics License Application (sBLA) to the FDA for approval under the traditional pathway on the same day. In China, Eisai has initiated submission of data for BLA to the National Medical Products Administration (NMPA) of China in December 2022. In Japan, Eisai plans to submit a marketing authorization application by the end of Eisai's fiscal year 2022, which ends March 31, 2023.
Eisai serves as the lead of lecanemab development and regulatory submissions globally with both Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making authority.
(1) CDR-SB is a numeric scale used to quantify the various severity of symptoms of dementia. Based on interviews of people living with AD and family/caregivers, qualified healthcare professionals assess cognitive and functional performance in six areas: memory, orientation, judgment and problem solving, community affairs, home and hobbies, and personal care. The total score of the six areas is the score of CDR-SB, and CDR-SB is also used as an appropriate item for evaluating the effectiveness of therapeutic drugs targeting the early stages of AD.
Media Contacts:
Eisai Co., Ltd.
Public Relations Department
TEL: +81 (0)3-3817-5120
Eisai Europe, Ltd.
(Europe, Australia, New Zealand and Russia)
EMEA Communications Department
+44 (0) 786 601 1272
EMEA-comms@eisai.net
Biogen Inc.
Natacha Gassenbach
+ 1-857-777-6573
public.affairs@biogen.com
Investor Contacts:
Eisai Co., Ltd.
Investor Relations Department
TEL: +81 (0) 3-3817-5122
Biogen Inc.
Mike Hencke
+ 1-781-464-2442
IR@biogen.com
Source: Eisai
Sectors: BioTech
Copyright ©2023 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.
Related Press Release
Eisai to Present Research from Oncology Portfolio at The Society of Gynecologic Oncology (SGO) 2023 Annual Meeting on Women's Cancer
March 24 2023 12:22 JST
Eisai to Present New Lecanemab Data, Including Research Evaluating Safety Profile, Clinical Outcomes and Quality of Life Measures, as Well as Other Important Alzheimer's Disease Research, at the AD/PD 2023 Annual Meeting
March 23 2023 12:30 JST
Eisai Publishes Societal Value of Lecanemab Using Phase 3 Clarity AD Data in Peer-Reviewed Neurology and Therapy Journal
March 20 2023 10:18 JST
U.S. Veterans' Health Administration (VHA) Provides Coverage of LEQEMBI (lecanemab-Irmb) Two Months After LEQEMBI's FDA Accelerated Approval for Veterans Living with Early Stages of Alzheimer's Disease
March 14 2023 10:09 JST
Eisai Receives the "Basic Achievement Grand Prize" at the 2023 J-Win Diversity Award
March 10 2023 14:04 JST
Eisai Certified as a 2023 Health and Productivity Management Outstanding
March 09 2023 08:07 JST
FDA Accepts Eisai's Filing of a Supplemental Biologics License Application and Grants Priority Review for Traditional Approval of LEQEMBITM (lecanemab-irmb) for the Treatment of Alzheimer's Disease
March 06 2023 09:58 JST
Biogen Japan and Eisai Provide Update on Co-Promotion Of Multiple Sclerosis Treatments In Japan
March 02 2023 09:45 JST
Biologics License Application for Lecanemab Designated for Priority Review by China National Medical Products Administration
February 28 2023 14:28 JST
Dissolution of Bracco-Eisai Joint Venture
February 21 2023 13:02 JST
More Press release >>
Latest Press Release
MHI Thermal Systems Develops Electric-Driven Transport Refrigeration Units with Heat-Pump Heating System for Domestic EV Trucks
Mar 30, 2023 16:27 JST
Mitsubishi Power Supporting Efficient Utilization of Hydrogen in the Petroleum Refining Process
Mar 30, 2023 16:00 JST
Hitachi Energy to support the transmission of increasing volumes of sustainable electricity to California
Mar 30, 2023 15:00 JST
Toyota: Sales, Production, and Export Results for February 2023
Mar 30, 2023 13:36 JST
Hitachi Vantara and Golden Grove Nursery Harness Data-Driven Analytics for More Sustainable Water Management
Mar 29, 2023 16:17 JST
Whitbread and Fujitsu sign a multimillion technology service partnership deal to bolster IT services in Premier Inn and restaurant brands
Mar 29, 2023 16:16 JST
JCB and Joint Stock Commercial Bank for Foreign Trade of Vietnam launch VCB JCB Platinum Credit Card in Vietnam
Mar 29, 2023 16:00 JST
Mazda Joins Research Association of Biomass Innovation for Next Generation Automobile Fuels
Mar 29, 2023 11:44 JST
NEC Technology Successfully Predicts High Risk Areas for Presence of Landmines
Mar 29, 2023 10:09 JST
Mitsubishi Shipbuilding Holds Launch Ceremony in Shimonoseki for Demonstration Test Ship for Liquefied CO2 Transport
Mar 28, 2023 14:07 JST
MHI Awarded 7-Year Long Term Service Agreement for 400 MW Combined Cycle Power Plant in Bangladesh
Mar 28, 2023 13:55 JST
Toyota to Establish a New Company to Promote the Fuji Motorsports Forest Project
Mar 28, 2023 13:42 JST
Asahi Kasei and NEC establish analysis platform utilizing secure computation technology for secure data collaboration between companies
Mar 28, 2023 11:14 JST
Fujitsu launches new cloud-based platform for healthcare sector in Japan, promoting personalized healthcare and drug development
Mar 28, 2023 10:17 JST
DENSO Wins Silver Medal at the 10th International Abilympics
Mar 27, 2023 19:37 JST
Hitachi Continuously Selected as CDP Supplier Engagement Leader
Mar 27, 2023 18:52 JST
Educational Manga Prepared as Teaching Tool for school child: "The Secrets of SDGs - Affordable and Clean Energy"
Mar 27, 2023 15:21 JST
Mazda: Conclusion of offsite corporate power purchase agreement (PPA) on solar power generation
Mar 27, 2023 14:52 JST
Eisai to Present Research from Oncology Portfolio at The Society of Gynecologic Oncology (SGO) 2023 Annual Meeting on Women's Cancer
Mar 24, 2023 13:22 JST
Mitsubishi Corporation: PoC Launched in Portland, Oregon to Develop Smart Multifamily Apartment
Mar 24, 2023 11:02 JST
More Latest Release >>